TY - JOUR
T1 - GLIOGENE - An international consortium to understand familial glioma
AU - Malmer, Beatrice
AU - Adatto, Phyllis
AU - Armstrong, Georgina
AU - Barnholtz-Sloan, Jill
AU - Bernstein, Jonine L.
AU - Claus, Elizabeth
AU - Davis, Faith
AU - Houlston, Richard
AU - Il'yasova, Dora
AU - Jenkins, Robert
AU - Johansen, Christoffer
AU - Lai, Rose
AU - Lau, Ching
AU - McCarthy, Bridget
AU - Nielsen, Hanne
AU - Olson, Sara H.
AU - Sadetzki, Siegal
AU - Shete, Sanjay
AU - Wiklund, Fredrik
AU - Wrensch, Margaret
AU - Yang, Ping
AU - Bondy, Melissa
PY - 2007/9/1
Y1 - 2007/9/1
N2 - Evidence for familial aggregation of glioma has been documented in both case-control and cohort studies and occurs apart from the well-described rare inherited genetic syndromes involving glioma: neurofibromatosis type 1 and 2, tuberous sclerosis, Turcot's syndrome, and Li-Fraumeni syndrome. Nonsyndromic glioma families have been studied but no genes have been identified in the two published linkage studies of familial glioma probably due to the small number of families. Because glioma is a rare but devastating cancer, and a family history of glioma has been observed in ∼5% of the cases, we initiated an international consortium to identify glioma families not affected by syndromes to better understand the inherited factors related to this disease. The international consortium GLIOGENE is an acronym for "glioma gene" and includes 15 research groups in North America, Europe, and Israel to study familial glioma. The overarching goal is to characterize genes in glioma families using a genome-wide single-nucleotide polymorphism approach and conducting linkage analysis to identify new genomic regions or loci that could harbor genes important for gliomagenesis. Here, we review the rationale for studying familial glioma and our proposed strategy for the GLIOGENE study.
AB - Evidence for familial aggregation of glioma has been documented in both case-control and cohort studies and occurs apart from the well-described rare inherited genetic syndromes involving glioma: neurofibromatosis type 1 and 2, tuberous sclerosis, Turcot's syndrome, and Li-Fraumeni syndrome. Nonsyndromic glioma families have been studied but no genes have been identified in the two published linkage studies of familial glioma probably due to the small number of families. Because glioma is a rare but devastating cancer, and a family history of glioma has been observed in ∼5% of the cases, we initiated an international consortium to identify glioma families not affected by syndromes to better understand the inherited factors related to this disease. The international consortium GLIOGENE is an acronym for "glioma gene" and includes 15 research groups in North America, Europe, and Israel to study familial glioma. The overarching goal is to characterize genes in glioma families using a genome-wide single-nucleotide polymorphism approach and conducting linkage analysis to identify new genomic regions or loci that could harbor genes important for gliomagenesis. Here, we review the rationale for studying familial glioma and our proposed strategy for the GLIOGENE study.
UR - http://www.scopus.com/inward/record.url?scp=34548862570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548862570&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-07-0081
DO - 10.1158/1055-9965.EPI-07-0081
M3 - Short survey
C2 - 17855690
AN - SCOPUS:34548862570
SN - 1055-9965
VL - 16
SP - 1730
EP - 1734
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 9
ER -